AstraZeneca picks up new vaccine technology originally intended to target Covid
Scientists at Imperial College London are partnering with AstraZeneca to develop a new vaccine technology – originally intended for targeting Covid-19 – that will aim to treat cancer, heart conditions and other non-infectious diseases and illnesses.